Investigational Drug Information for Arimoclomol
✉ Email this page to a colleague
What is the development status for investigational drug Arimoclomol?
Arimoclomol is an investigational drug.
There have been 10 clinical trials for Arimoclomol.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 31st 2018.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are Orphazyme, University of Kansas Medical Center, and University College, London.
There are forty US patents protecting this investigational drug and eight hundred and twenty-four international patents.
Summary for Arimoclomol
| US Patents | 40 |
| International Patents | 824 |
| US Patent Applications | 347 |
| WIPO Patent Applications | 155 |
| Japanese Patent Applications | 22 |
| Clinical Trial Progress | Phase 3 (2018-07-31) |
| Vendors | 41 |
Recent Clinical Trials for Arimoclomol
| Title | Sponsor | Phase |
|---|---|---|
| Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial | Orphazyme | Phase 3 |
| Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial | University College, London | Phase 3 |
| Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial | University of Kansas Medical Center | Phase 3 |
Clinical Trial Summary for Arimoclomol
Top disease conditions for Arimoclomol
Top clinical trial sponsors for Arimoclomol
US Patents for Arimoclomol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Arimoclomol | ⤷ Try a Trial | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder | Axovant Sciences GmbH (Basel, CH) | ⤷ Try a Trial |
| Arimoclomol | ⤷ Try a Trial | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | Axovant Sciences GmbH (Basel, CH) | ⤷ Try a Trial |
| Arimoclomol | ⤷ Try a Trial | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | ENTERIN LABORATORIES, INC. (Merion, PA) | ⤷ Try a Trial |
| Arimoclomol | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Arimoclomol | ⤷ Try a Trial | Methods of treating and preventing gastrointestinal motility disorders using aminosterols | Enterin Laboratories, Inc. (Merion, PA) | ⤷ Try a Trial |
| Arimoclomol | ⤷ Try a Trial | Methods of treating and/or preventing neurodevelopmental disorders (autism) using aminosterols | Enterin Laboratories, Inc. (Merion, PA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Arimoclomol
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Arimoclomol | Argentina | AR104982 | 2035-06-12 | ⤷ Try a Trial |
| Arimoclomol | Australia | AU2016276966 | 2035-06-12 | ⤷ Try a Trial |
| Arimoclomol | Australia | AU2021269398 | 2035-06-12 | ⤷ Try a Trial |
| Arimoclomol | Canada | CA2989343 | 2035-06-12 | ⤷ Try a Trial |
| Arimoclomol | China | CN109562085 | 2035-06-12 | ⤷ Try a Trial |
| Arimoclomol | European Patent Office | EP3307260 | 2035-06-12 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
